Why bother with a practice formulary?
Reilly, P.; Annesley, E.
Practitioner 236(1516): 740-742
1992
ISSN/ISBN: 0032-6518 PMID: 1454747 Document Number: 403905
Document emailed within 1 workday
Related Documents
Wang, Y.R.; Pauly, M.V. 2005: Prescription drug formulary design, preferred-product marketshare, and formulary noncompliance: a study of proton-pump inhibitors Managed Care Interface 18(8): 39-45Dowell, J.S.; Snadden, D.; Dunbar, J.A. 1995: Changing to generic formulary: how one fundholding practice reduced prescribing costs Bmj 310(6978): 505-508
Bower, C.I.; Lester-Smith, D.; Elliott, E.J. 2010: Congenital anomalies--why bother? Medical Journal of Australia 192(6): 300-301
Keeley, F.X. 2012: Endoscopic biopsy of upper tract tumors: why bother? Canadian Journal of Urology 19(6): 6566
Charette, N.; Leclercq, I.A. 2010: Why should the gastroenterologist bother about obesity? An oncologic point of view Acta Gastro-Enterologica Belgica 73(4): 504-509
Knudsen, N.; Schulman, S.; Fowler, R.; van den Hoek, J. 1984: Why bother with stop-smoking education for lung cancer patients? Oncology Nursing Forum 11(3): 30-33
Smith, S.D. 2006: Recasting the lowly formulary Minnesota Medicine 89(4): 28-29; 44
Martucci, H.J. 1987: Different approach to the formulary needed American Journal of Hospital Pharmacy 44(5): 1026
Berod, T.; Vetel, J.M.; Sauvageon, A. 1990: Compliance with a formulary for geriatric patients American Journal of Hospital Pharmacy 47(8): 1751-1752
DiPiro, J.T.; Steele, J.C. 1987: Rational formulary selection of antimicrobials American Journal of Hospital Pharmacy 44(1): 74
Ford, D.B.; Bergerson, S.L.; Henderson, P.; Murphy, J.; Peter, J. 1989: Establishing an enteral product formulary Journal of the American Dietetic Association 89(5): 681-683
Navarro, R.P. 1999: Raising the bar in the formulary decision process Managed Care Interface 12(7): 51; 54
Lilja, J. 1979: Drug product selection by formulary committees in Sweden American Journal of Hospital Pharmacy 36(8): 1042 1044
Montanari, L. 1979: Fifth supplement to the United States Pharmacopoeia XIX and National Formulary XIV Bollettino Chimico Farmaceutico 118(10): 585-593
Abourjaily, P.; Gouveia, W.A.; Selker, H.P.; Zucker, D.R. 2005: Evaluating the nondrug costs of formulary coverage restrictions Managed Care 14(8): 50-7 62
Andriole, V.T.; Ryan, J.L. 1982: An approach to formulary consideration of antimicrobial agents: the tetracyclines Hospital Formulary 17(7): 965-968
Smith, E.B.; Hope, S.M.; Halstead, S.K.; Ford, W.M. 1990: Integration of formulary systems with centralized pharmaceutical procurement Hospital Formulary 25(2): 193-196; 198
Owens, R.C.; Ambrose, P.G.; Quintiliani, R. 1997: Ceftazidime to cefepime formulary switch: pharmacodynamic and pharmacoeconomic rationale Connecticut Medicine 61(4): 225-227
Richerson, M.A.; Ambrose, P.G.; Quintiliani, R.; Nightingale, C.H. 1998: Formulary review of the carbapenems: comparison of imipenem/cilastatin and meropenem Connecticut Medicine 62(3): 165-169
Smith, M.C.; Maclayton, D.W. 1977: The effect of closing a Medicaid formulary on the prescription of analgesic drugs Hospital Formulary 12(1): 36-38; 41